

**IMPLEMENTATION ROLLING PLAN
Regulation (EU) 2017/745 and Regulation (EU) 2017/746**

This rolling plan contains a list of identified essential implementing acts and other relevant initiatives that the Commission has adopted or intends to adopt in the future. This plan is divided into two sections: implementing acts, and other actions/initiatives. This document is subject to quarterly review in order to provide national authorities and stakeholders with the most updated information.

This document shall be read in conjunction with the “MDR/IVDR roadmap” adopted by the Competent Authorities for Medical Devices (CAMD) in cooperation with the Commission (available at <https://www.camd-europe.eu/regulatory/medical-devices-regulation-vitro-diagnostics-regulation-mdr-ivdr-roadmap>). A list of ongoing MDCG guidance documents is available at <https://ec.europa.eu/docsroom/documents/37921>.

NOTE: Regulation (EU) 2020/561 of the European Parliament and of the Council deferred by one year the date of application of Regulation (EU) 2017/745, until 26 May 2021.

Latest update: May 2020

No.	Subject	Legal basis	Description	Expected timelines (expected date of final adoption/date of accomplishment)	State-of-play/Next step
IMPLEMENTING ACTS					
1	Notified bodies scope of designation	Article 42(13) MDR Article 38(13) IVDR	Commission Implementing Regulation (EU) 2017/2185 Definition of the list of codes and corresponding types of devices for the purpose of specifying the scope of the designation of notified bodies. This action is an essential pre-condition for the launch of the designation procedure for Notified Bodies	24 November 2017	Published on 24 November 2017 COMPLETED
2	Reprocessing of single-use medical devices	Article 17(5) MDR	Commission implementing act Common specifications laying down requirements related to reprocessing of single-use devices concerning: – risk management, including the analysis of the construction and material, related properties of the device (reverse engineering) and procedures to detect changes in the design of the original device as well as of its planned application after reprocessing, – the validation of procedures for the entire process, including cleaning steps, – the product release and performance testing, – the quality management system, – the reporting of incidents involving devices that have been reprocessed, and – the traceability of reprocessed devices.	Q3 2020	Undergoing formal adoption procedure.
3	Common specifications for products without a medical purpose	Articles 1(2) and 9(1) MDR	Commission implementing act Common specifications (CS) addressing for any of the groups of products listed in Annex XVI of the MDR, at least, application of risk management as set out in Annex I and, where necessary, clinical evaluation regarding safety. Application of MDR to Annex XVI products depends on the adoption of CS.	Q4 2020	In planning.
4	Setting up of expert panels	recital 94 Article 106(1) MDR	Commission Implementing Decision (EU) 2019/1396 Making provision for expert panels to be designated. Based on this implementing act, the selection of experts will be carried out. Expert panels are tasked inter alia with the delivery of opinions on the clinical evaluation of certain high-risk devices in the context of the pre-market scrutiny. Tasks of expert panels are described in Article 106(10).	Q3 2019	Published on 10 September 2019. COMPLETED
5	Setting up of expert laboratories	Article 106(7) MDR	Commission implementing act Designation of expert laboratories. Tasks of expert laboratories are described in Article 106(7). It shall be noted that the designation of expert laboratories is not mandatory.	Q3 2020	In planning.

6	Setting up of new structures under IVDR: - EU reference laboratories	recital 94 Articles 48(6), 100(1) and (3) IVDR, Article 113(d) IVDR	Implementing Act (no comitology involved) Designation of EU reference laboratories, active in the IVD field. Tasks are described in Article 100. Designation may take place no earlier than 25 November 2020, according to IVDR Article 113(d).	Q1 2021	Nominations in preparation				
7	Rules to facilitate fulfilment of tasks by EU reference laboratories and to ensure their compliance with criteria	Article 100(8)(a)	Implementing Act Rules to facilitate application of IVDR Article 100 (2) listing the tasks of the EURLs; rules to ensure compliance with criteria for an EURL listed in IVDR Article 100 (4). Date of application of the act may not be earlier than 25 November 2020 according to IVDR Article 113(d).	Q3 2020	In planning.				
9	Fees for EURL services	Article 100(8)(b) IVDR	Implementing Act Definition of rules for fees for the advice/testing activities performed by EURL. Date of application of the act may not be earlier than 25 November 2020 according to IVDR Article 113(d).	Q3 2020	In planning.				
10	Unique Device Identification (UDI) System: designation of issuing entities	Article 27(2) MDR Article 24(2) IVDR	Commission Implementing Decision (EU) 2019/939 Designation of one or more entities to operate a system for assignment of UDIs ('issuing entity').	6 June 2019	Published on 6 June 2019. COMPLETED				
11	EUDAMED	Article 33(8) MDR Article 30(1) IVDR	Commission implementing act Definition of detailed arrangements necessary for the setting up and maintenance of Eudamed. This IA is mainly related to support, change management and maintenance rules	Q4 2020	In planning.				
12	Common specifications for IVD Class D	Article 9 and 48(6) IVDR	Commission implementing act Common Specifications for IVD Class D in the context of the scrutiny mechanism for high risk devices	Q3 2020	In planning.				
ACTIONS/INITIATIVES (OTHER THAN IMPLEMENTING REGULATIONS/ACTS)									
1	Notified Bodies designation		Designation of Notified Bodies under the MDR and IVDR. Designation of Notified Bodies under the Regulations is a pre-condition for carrying out conformity assessments under those Regulations. List of notified bodies under MDR/IVDR available at: https://ec.europa.eu/growth/tools-databases/nando/index.cfm?fuseaction=directive.main	Notified bodies are designated on a rolling basis.	See New Approach Notified and Designated Organisations (NANDO).				
5	EUDAMED go-live	Article 34 MDR	Eudamed may go-live from the moment a notice is published in the Official Journal of the European Union after a positive independent audit was performed that satisfies the MDCG	Notice to be published in 2022.	Deployment of fully functional EUDAMED intended to take place in 2022. In agreement with the MDCG, the Commission has pledged to make available the six modules on a rolling basis as soon as each module becomes operational.				
3	EUDAMED: drawing up of functional specifications	Article 34(1) MDR	Functional specifications for Eudamed, to be drawn up by the Commission, in cooperation with the MDCG.	Q1 2019 (high-level functional specifications)	High-level functional specifications publically issued on the Commission website in March 2019.				
4	EUDAMED: Audit of functional specifications	Article 34(2) MDR	Independent audit report based on which the Commission shall inform the MDCG that Eudamed has achieved full functionality and meets the drawn up functional specifications.	Should be finalised in 2022.	Pending.				
6	EUDAMED: Setting of helpdesk	MDR Art 33(8)	Detailed arrangements necessary for the setting up and maintenance of Eudamed means at least the setting of an helpdesk/application support for Eudamed (good IT practice and obligation under the implementing act).	Before Eudamed go-live	In planning.				

